Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease

Proteins: Structure, Function and Genetics

Volumn 38, Issue 1, 2000, Pages 29-40

  Li, Mi ^a,b   Morris, Garrett M ^c   Lee, Taekyu ^c   Laco, Gary S ^c,d   Wong, Chi Huey ^c   Olson, Arthur J ^c   Elder, John H ^c   Wlodawer, Alexander ^a   Gustchina, Alla ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Drug design; Enzymes; Inhibition constant; Structure comparison

Indexed keywords

MUTANT PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; VIRUS ENZYME;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME STRUCTURE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ASPARTIC ENDOPEPTIDASES; BINDING SITES; CATS; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HIV PROTEASE; HIV-1; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; MACROMOLECULAR SUBSTANCES; MODELS, MOLECULAR; POINT MUTATION; PROTEIN CONFORMATION; THERMODYNAMICS;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033970624     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0134(20000101)38:1<29::AID-PROT4>3.0.CO;2-N     Document Type: Article

References (42)

1. Pedersen NC, Ho EW, Brown ML, Yamamoto JK. Isolation of T-lymphotrophic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987;235:790-793.
2. Pedersen NC. The Feline Immunodeficiency Virus. In: Levy, JA, editor. The Retroviridae. New York: Plenum Press; p 181-228.
3. Elder JH, Dean GA, Hoover EA, et al. Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1998;14:797-801.
4. Carry RF, Krieg AM, Cheevers WP et al. Retroviruses and their roles in chronic inflammatory diseases and autoimmunity. Levy, JA, editor. The Retroviridae. New York: Plenum Press; p 491-603.
5. Vandamme A-M, Van Vaerenbergh K, De Clercq E. Anti-human immunodeficiency virus drug combination strategies. Antivir Chem Chemother 1998;9:187-203.
6. Bendinelli M, Pistello M, Lombardi S et al. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 1995;8:87-112.
7. Bennett M, Hart CA. Feline immunodeficiency virus infection - a model for HIV and AIDS? J Med Microbiol 1998;42:233-236.
8. Elder JH, Phillips TR. Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections. Adv Virus Res 1995;45:225-247.
9. McCune JM. Animal models of HIV-1 disease. Science 1997;278: 2141-2142.
10. Willett BJ, Flynn JN, Hosie MJ. FIV infection of the domestic cat: an animal model for AIDS. Immunol Today 1997;18:182-189.
11. Deeks SG, Volberding PA. HIV-1 protease inhibitors. AIDS Clin Rev 1997;98:145-185.
12. Olson AJ, Goodsell DS. Automated docking and the search for HIV protease inhibitors. SAR QSAR Environ Res 1998;8:273-285.
13. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998;27:249-284.
14. Erickson JW. The not-so-great escape. Nat Struct Biol 1995;2:523-529.
15. Ribeiro RM, Bonhoeffer S, Nowak MA. The frequency of resistant mutant virus before antiviral therapy. AIDS 1998; 12:461-465.
16. Kaplan AH. Constraints on the sequence diversity of the protease of human immunodeficiency virus type 1: a guide for drug design. AIDS Res Hum Retroviruses 1996;12:849-853.
17. Condra JH, Schleif WA, Blahy OM et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-571.
18. Erickson JW, Burt SK. Structural mechanisms of HIV drug resistance. Annu Rev Pharmacol Toxicol 1996;36:545-571.
19. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Intl Antiviral News 1997; 5,129-142.
20. Roberts NA, Craig JC, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice. AIDS 1998;12:453-460.
21. Wlodawer A, Gustchina A, Reshetnikova L et al. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat Struct Biol 1995;2:480-488.
22. Gustchina A, Kervinen J, Powell DJ, Zdanov A, Kay J, Wlodawer A. Structure of equine infectious anemia virus proteinase complexed with an inhibitor. Protein Sci 1996;5:1453-1465.
23. Slee DH, Laslo KL, Elder JH et al. Selectivity in the inhibition of HIV and FIV protease: Inhibitory and mechanistic studies of pyrrolidine-containing a-keto amide and hydroxyethylamine core structures. J Am Chem Soc 1995;117:11867-11878.
24. Kervinen J, Lubkowski J, Zdanov A et al. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV. Protein Sci 1998;7:2314-2323.
25. Lee T, Laco GS, Torbett BE, Fox HS, Lerner D, Elder JH, Wong C-H. Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broadbased protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Proc Natl Acad Sci USA 1998;95:939-944.
26. Talbott RL, Sparger EE, Lovelace KM et al. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci USA 1989;86:5743-5747.
27. Ratner L, Fisher A, Jagodzinski LL et al. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses 1987;3:57-69.
28. Gulnik SV, Suvorov LI, Liu B et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995;34:9282-9287.
29. Ratner L, Haseltine W, Patarca R et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985;313:277-284.
30. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307-326.
31. Brünger A. X-PLOR version 3.1: A System for X-ray crystallography and NMR. New Haven, CT: Yale University Press; 1992.
32. Sheldrick GM, Schneider TR. SHELXL: High-resolution refinement. Meth Enzymol 1997;277:319-343.
33. Brünger AT. The free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992;355:472-474.
34. Jones TA, Kieldgaard M. Electron-density map interpretation. Methods Enzymol 1997;277:173-208.
35. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PRO-CHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283-291.
36. Lutz M. Programming Python. Sebastopol, CA: O'Reilly & Associates; 1996.
37. Python Language Website, http://www.python.org/.
38. InsightII 97.0 edition, San Diego, CA: Biosym Technologies; 1998.
39. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157-162.
40. Jaskolski M, Tomasselli AG, Sawyer TK et al. Structure at 2.5 Å resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry 1991;30:1600-1609.
41. Schnolzer M, Rackwitz HR, Gustchina A et al. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis. Virology 1996;224:268-275.
42. Jadhav PK, Ala P, Woerner FJ et al. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J Med Chem 1997;40:181-191.